Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): A final report on 60 cases

Mario Airoldi, Massimiliano Garzaro, Fulvia Pedani, Oliviero Ostellino, Giovanni Succo, Giuseppe Riva, Matteo Sensini, Nertila Naqe, Elisa Bellini, Luca Raimondo, Giancarlo Pecorari

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme. MATERIALS AND METHODS: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m on day 1+VNB at 25 mg/m on day 1 and 8, at 3-week intervals. RESULTS: Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo). CONCLUSIONS: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

Original languageEnglish
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
DOIs
Publication statusAccepted/In press - Aug 1 2014

Fingerprint

Salivary Glands
Cisplatin
Drug Therapy
Neoplasms
Therapeutics
Survival
Adenocarcinoma
vinorelbine
Cohort Studies
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM) : A final report on 60 cases. / Airoldi, Mario; Garzaro, Massimiliano; Pedani, Fulvia; Ostellino, Oliviero; Succo, Giovanni; Riva, Giuseppe; Sensini, Matteo; Naqe, Nertila; Bellini, Elisa; Raimondo, Luca; Pecorari, Giancarlo.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, 01.08.2014.

Research output: Contribution to journalArticle

Airoldi, Mario ; Garzaro, Massimiliano ; Pedani, Fulvia ; Ostellino, Oliviero ; Succo, Giovanni ; Riva, Giuseppe ; Sensini, Matteo ; Naqe, Nertila ; Bellini, Elisa ; Raimondo, Luca ; Pecorari, Giancarlo. / Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM) : A final report on 60 cases. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2014.
@article{d2854d3062434ddca5a1fadf5ead15c6,
title = "Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): A final report on 60 cases",
abstract = "OBJECTIVES: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme. MATERIALS AND METHODS: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m on day 1+VNB at 25 mg/m on day 1 and 8, at 3-week intervals. RESULTS: Seventy percent of the patients received DDP+VNB as the first-line CT and 30{\%} of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7{\%} of the patients achieved a complete response, 24{\%} achieved a partial response, 33{\%} achieved an no change, and 36{\%} achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5{\%} achieved a PR, 33{\%} achieved an NC, and 62{\%} achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54{\%}) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo). CONCLUSIONS: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.",
author = "Mario Airoldi and Massimiliano Garzaro and Fulvia Pedani and Oliviero Ostellino and Giovanni Succo and Giuseppe Riva and Matteo Sensini and Nertila Naqe and Elisa Bellini and Luca Raimondo and Giancarlo Pecorari",
year = "2014",
month = "8",
day = "1",
doi = "10.1097/COC.0000000000000112",
language = "English",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM)

T2 - A final report on 60 cases

AU - Airoldi, Mario

AU - Garzaro, Massimiliano

AU - Pedani, Fulvia

AU - Ostellino, Oliviero

AU - Succo, Giovanni

AU - Riva, Giuseppe

AU - Sensini, Matteo

AU - Naqe, Nertila

AU - Bellini, Elisa

AU - Raimondo, Luca

AU - Pecorari, Giancarlo

PY - 2014/8/1

Y1 - 2014/8/1

N2 - OBJECTIVES: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme. MATERIALS AND METHODS: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m on day 1+VNB at 25 mg/m on day 1 and 8, at 3-week intervals. RESULTS: Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo). CONCLUSIONS: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

AB - OBJECTIVES: Recurrent or metastatic salivary gland malignancies (RMSGM) are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP+VNB as a first-line or second-line scheme. MATERIALS AND METHODS: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first-line or second-line chemotherapy (CT), for a maximum of 6 cycles: DDP at 80 mg/m on day 1+VNB at 25 mg/m on day 1 and 8, at 3-week intervals. RESULTS: Seventy percent of the patients received DDP+VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP+VNB, 7% of the patients achieved a complete response, 24% achieved a partial response, 33% achieved an no change, and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC, and 62% achieved a PD. The median overall survival period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first-line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 mo). CONCLUSIONS: Adenocarcinomas show the best response and prognosis with DDP+VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT.

UR - http://www.scopus.com/inward/record.url?scp=84905317369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905317369&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000112

DO - 10.1097/COC.0000000000000112

M3 - Article

AN - SCOPUS:84905317369

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

ER -